​ACS CAN this week co-signed an ad in the N.Y. Times.

New blood-based screening technologies, called multi-cancer early detection tests, could help define the next era of the War on Cancer – if FDA approved and proven to have clinical benefit. 

Read the advertisement here: https://t.co/SQy7N60dT1

Read the tweet here: https://t.co/Pl1xPG1uc3